An economic analysis of premarriage prevention of hepatitis B transmission in Iran by Adibi, Peyman et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
An economic analysis of premarriage prevention of hepatitis B 
transmission in Iran
Peyman Adibi, Mohammadreza Rezailashkajani*, Delnaz Roshandel, 
Negar Behrouz, Shahin Ansari, Mohammad Hossein Somi, Saeed Shahraz 
and Mohammad Reza Zali
Address: Research Center for Gastroenterology and Liver Disease, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
Email: Peyman Adibi - payad2000@yahoo.com; Mohammadreza Rezailashkajani* - docreza@yahoo.com; 
Delnaz Roshandel - delnaz53@yahoo.com; Negar Behrouz - negar_behrouz@yahoo.com; Shahin Ansari - shahin_a20@yahoo.com; 
Mohammad Hossein Somi - mhosseinsina@yahoo.com; Saeed Shahraz - sshahraz@yahoo.com; Mohammad Reza Zali - nnzali@hotmail.com
* Corresponding author    
Abstract
Background: To assess the economic aspects of HBV (hepatitis B virus) transmission prevention
for premarriage individuals in a country with cultural backgrounds like Iran and intermediate
endemicity of HBV infection.
Methods: A cost-effectiveness analysis model was used from the health care system and society
perspectives. The effectiveness was defined as the number of chronic HBV infections averted owing
to one of the following strategies:
1) HBsAg screening to find those would-be couples one of whom is HBsAg positive and putting
seronegative subjects on a protection protocol comprising HBV vaccination, single dose HBIG and
condom protection.
2) HBsAg screening as above, in addition to performing HBcAb screening in the HBsAg negative
spouses of the HBsAg positive persons and giving the protocol only to HBcAb negative ones.
Sensitivity and threshold analyses were conducted.
Results: The cost of each chronic infection averted was 202$ and 197$ for the strategies 1 and 2,
respectively. Sensitivity analysis showed that strategy 2 was always slightly cheaper than strategy 1.
The discounted threshold value for the lifetime costs of chronic liver disease, above which the
model was cost saving was 2818$ in strategy 1 and 2747$ in strategy 2.
Conclusions: Though premarriage prevention of HBV transmission in the countries with cultural
backgrounds similar to Iran seems cost saving, further studies determining precise costs of HBV
infection in Iran can lead to a better analysis.
Background
Hepatitis B is an important health problem and a major
cause of acute and chronic hepatitis, cirrhosis and hepato-
cellular carcinoma. Approximately 30% of the world
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population (1.8 billion people) have the serologic evi-
dence of HBV infection of whom 350 million are esti-
mated to suffer from chronic HBV (hepatitis B virus)
infection; at least 500,000 chronically infected people die
of liver malignancy and cirrhosis each year [1].
According to Iranian studies, about 22% to 37% of gen-
eral population in Iran are HBcAb positive [2,3] (e.g. pre-
vious exposure to HBV) and about 1.3% to 8.69% of the
population are chronic HBV carriers [2-6]. Compared to
the United States where HBV is the cause of 25% of
chronic hepatitis cases, HBV accounts for up to 70% to
80% of chronic hepatitis cases in Iran [7]. Therefore, HBV
alone is the leading cause of chronic liver disease (CLD)
in Iran and it is evident that HBV transmission prevention
can be one of the health priorities in the country.
We believe that major routes of HBV transmission, local
epidemiological factors and the already performed pre-
vention programs of each region are among important
factors in identifying the populations at risk of the infec-
tion and planning the region-specific prevention strate-
gies. In Iran, universal neonatal vaccination against HBV
started in 1993 according to WHO recommendations. It
means that Iranians 10 years of age or older at the time of
this study received no prevention services against HBV
and so most of them could contract the infection if
attacked by the virus. For this at-risk population, several
preventive strategies can be suggested which of course
should have economic justification. Premarriage trans-
mission prevention can be considered as one of the possi-
ble solutions to protect this population though it should
not be regarded as the only or the best solution available.
Sexual contact is one of the common routes of HBV trans-
mission. In Iran, due to a particular cultural and religious
background, homosexuality is not known as a common
phenomenon compared to the western countries. For the
same reasons, it is very unlikely for an individual to have
sexual contact (especially in the form of intercourse) with
his/her would-be spouse. On the other hand, almost all
premarriage individuals (those considering legal mar-
riage) are obliged by Iranian law to undergo a predefined
battery of screening tests in government-designated labo-
ratories; this can make premarriage individuals an accessi-
ble group for a preventive intervention. Finally, since
most premarriage individuals are in young age groups,
they have a rather long life expectancy, which allows
enough time for them to suffer from chronic complica-
tions of HBV infection in productive years of life.
We decided to perform this study to provide health policy
makers in Iran and those countries with similar demo-
graphic conditions (especially in the Middle East) with an
economic analysis of premarriage prevention of hepatitis
B transmission.
Methods
Model
The economics of performing two rather similar strategies
in addition to no intervention strategy were compared
using a decision tree (Fig. 1). The software used for analy-
sis was Decision Analysis by TreeAge (DATA™, William-
stown, MA, USA).
As shown in Fig. 1, the overall options available for pre-
marriage individuals can be one of the major strategies
mentioned below:
1. Screening all premarriage individuals for HBsAg and
then performing the following prevention protocol
(marked as P.P. in Fig. 1) for HBsAg negative individuals
whose would-be spouse is HBsAg positive:
a. Three-dose HB vaccine (0, 1, 6 mo)
b. Single dose HBIG injection
c. Using condoms (2 boxes/mo) during all intercourses
for 7 months
d. Measurement of HBsAb (hepatitis B surface antibody)
1 month after the 3rd dose of the vaccine
e. An extra dose vaccine and additional condom protec-
tion for another month for the persons whose HBsAb is
not in protective ranges (lower than 10 IU/l)
No protection protocol is considered for those couples
who are both HBsAg positive or negative.
2. Screening all premarriage individuals for HBsAg fol-
lowed by rescreening of the HBsAg negative spouses of
HBsAg positive persons for HBcAb and finally performing
the prevention protocol (e.g. the a to e steps above) only
for HBcAb (and HBsAg) negative individuals whose
would-be spouse is HBsAg positive.
No protection protocol is considered for those couples
who are both HBsAg positive or negative.
3. No screening and no prevention.
The main analysis considered the perspective of health
care system. However, in the final analysis (including the
sensitivity analysis), a threshold analysis was performed
from societal perspective. The results were expressed by
the cost per chronic infection (e.g. more than 6 months
HBsAg positive) averted (e.g. average cost effectiveness).BMC Infectious Diseases 2004, 4:31 http://www.biomedcentral.com/1471-2334/4/31
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Assumptions
The assumptions in the model included:
1) HBV vaccination is not harmful for the individual or
community;
2) the efficacy of preventive methods such as 3-dose HB
vaccine, HBIG injection and condoms in preventing sex-
ual transmission of HBV do not significantly vary by geo-
graphic region;
3) the compliance of the population for receiving the pre-
ventive methods is 100%;
4) the preventive methods are available throughout the
country and can cover 100% of the population;
5) HBcAb positive persons are not at risk of HBV infection
and this group will not be considered for receiving preven-
tive measures;
6) all HBsAg positive individuals are HBcAb positive too;
The decision tree model for premarriage prevention of HBV sexual transmission Figure 1
The decision tree model for premarriage prevention of HBV sexual transmission. Two similar intervention strategies start with 
HBsAg screening of all premarriage individuals. HBsAg negative individuals whose would-be spouse is HBsAg positive are con-
sidered for further intervention. Strategy 2 contains additional screening for HBcAb and applying the preventive protocol (P.P.) 
-see text- only to those negative for HBcAb (assumed to be serosusceptible) whereas in strategy 1, no HBcAb screening 
occurs and the prevention protocol (P.P.) is immediately performed. Only important probabilities are depicted in the figure. P1, 
P2, P3, P4 are defined in Table 1. P.P. stands for the preventive protocol explained in methods section in text.BMC Infectious Diseases 2004, 4:31 http://www.biomedcentral.com/1471-2334/4/31
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7) the sensitivity and specificity of the screening tests (for
HBsAg and HBcAb) are 100%;
8) the average age at marriage is 25 years of age for both
sexes;
9) the costs associated with CLD are incurred during a 10-
year period starting at the age of 50 [1,24];
10) the transmission rate of HBV from men to women
and vice versa are equal;
11) premarriage individuals do not have intercourse
before marriage; and
12) Iran is located in a region with intermediate preva-
lence of hepatitis B.
Probabilities and costs
The probabilities included in the decision analysis model
(Table 1) were assumed to be of 2 types: 1) the probabili-
ties that do not significantly vary by geographic location
(e.g. the efficacy of 3-dose HB vaccine, HBIG injection and
condom in preventing sexual transmission of HBV) and
2) the ones that seem to be significantly different in vari-
ous geographic locations (e.g. HBsAg or HBcAb
prevalence rates in the society).
To have preliminary estimates of the latter category prob-
abilities, all available and accurate Iranian medical litera-
ture (published from 1993 to 2003) were reviewed. For
the former category probabilities, international resources
(PubMed) were included in addition to the Iranian
sources mentioned above. If a probability was not found
in medical literature, the consensus of an expert team
including 5 gastroenterologists collaborating with our
research center was considered as the base case value.
A review of Iranian studies showed that the prevalence of
HBsAg in general population varied from 1.2% to 8.69%
in different parts of Iran [2-6]. In this study, we considered
an average rate of 2% as the baseline in a range of 1% to
9% (Table 1). The Iranian studies also showed that the
prevalence of HBcAb varied from 15% to 37% in different
parts of Iran. Therefore, we assumed an average rate of
20% as the baseline in a range of 15% to 40% (Table 1)
[2,3].
The review of international and Iranian medical literature
revealed that the probability of being HBsAg positive for
an HBsAg positive person's spouse (P3) is about 4% to
15% [8-11]. We assumed a baseline probability of 5%.
(Table 1)
The probability of becoming HBsAg positive for an HBsAg
positive person's spouse after receiving the prevention
protocol (P4) was indirectly calculated by the formula
below:
P4 = P3 (1 - efficacy of preventive protocol)
The baseline value for the efficacy of the prevention pro-
tocol used in our model to protect against spouse-spouse
HBV transmission (3-dose HB vaccine, HBIG injection
and condom protection up to complete immunity) was
assumed to be 90%. The figure was reached by consider-
ing the values found in the literature for the efficacy of 3-
dose HB vaccine [12,13], HBIG injection [14-19] and
condom protection [20-23] which was finally modified
by consensus from the expert team described above. The
most pessimistic and optimistic estimations for the effi-
cacy of the prevention protocol were assumed to be 75%
and 100%, respectively. Therefore, the baseline value for
P4 was assumed to be 0.05% in a range of 0% to 1.25%.
The direct medical costs of interventions (Table 2) were
extracted from the resources and tariffs of Iranian Health
Ministry, Iran Pasteur Institute and Iranian Transfusion
Organization in 2003 (unpublished data) and were used
as baseline costs in the model. The indirect medical costs
of the intervention such as transportation and time costs
for the recipients of the preventive methods (to receive the
services) were assumed to be zero and were not included
in the model. The costs of the averted morbidity (HBV
infection especially chronic liver disease) were not directly
put in the model because of unavailability of relative Ira-
nian studies. However, as a solution to better analysis, the
latter costs were calculated as a final variable in a thresh-
old analysis, considering the fact that of the adults in
chronic carrier state, 15% will eventually develop chronic
liver disease (CLD) [1,24,25]. In most economic analyses,
the costs are modified for the outcomes occurring in the
future, a process called discounting. Considering the aver-
age age at marriage and the age at which CLD starts (see
assumptions) the cost of CLD calculated through the
threshold analysis was discounted by a discount rate of
3% to the beginning of the 10-year period of CLD devel-
opment. The costs are expressed in the text and tables in
US $ and Iranian Rials (1US $ = 8300 Iranian Rials). The
currency conversion rate reported here is the one for mid-
2003 when the study was performed.
Sensitivity analysis
Uncertainty management, which is one of the central
processes in decision-making, usually involves working
with probabilities that usually vary in different circum-
stances. Therefore, the outcome values and final decision
is prone to change when the value of probabilities change.
Sensitivity analysis is a method in which the final decisionBMC Infectious Diseases 2004, 4:31 http://www.biomedcentral.com/1471-2334/4/31
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and the value of outcomes are estimated while each prob-
ability (univariate) or combinations of probabilities
(multivariate) are varied in a reasonable range. This will
reveal the variables whose change the model is sensitive
to.
In this study, univariate sensitivity analysis was performed
for prevalence of HBsAg positivity in general population
(P1), prevalence of HBcAb positivity in general popula-
tion (P2), probability of becoming HBsAg positive for an
HBsAg positive person's spouse (P3) and probability of
becoming HBsAg positive for an HBsAg positive person's
spouse after receiving the prevention protocol (P4). Multi-
variate sensitivity analysis was performed for P1 and P2,
considering the fact that the two probabilities were
dependent. All of the direct medical costs of the interven-
tion (Table 2) were assumed to be constant in the sensitiv-
ity analyses.
The results of the above sensitivity analyses were evalu-
ated in respect of their impact on the value of the cost per
chronic HBV infection averted and the preference of strat-
egies 1 and 2.
Results
Having run the model for baseline values (Tables 1 and
2), the average cost effectiveness of strategies 1 (without
additional screening for HBcAb) and 2 (including addi-
tional screening for HBcAb) were 1,675,500 Rials (202 $)
and 1,633,200 Rials (197 $) for each chronic HBV infec-
tion prevented, respectively.
The worst-case analysis (e.g. setting all input probability
values so that they would act to decrease effectiveness and
increase the costs) was performed setting P1, P2 and P3 at
their minimum values and P4 at its maximum value. It
showed that the average cost-effectiveness ratio of strategy
1 would be 2,460,204 Rials (296 $) and that of strategy 2
would be 2,440,015 Rials (293 $) in the worst case. It is
noteworthy that the costs were not varied and were kept at
their baseline values in this sensitivity analysis.
A threshold analysis was performed to find the threshold
value for the lifetime cost of CLD for one individual (from
a societal perspective) below which the interventions in
the model were not cost saving (e.g. the net benefit was
negative). The analysis was performed keeping all other
variables at their baseline values. The preliminary (non-
discounted) threshold value for the lifetime cost of CLD
was found to be 11,170,000 Rials (1346 $) and
10,888,000 Rials (1312 $) using strategies 1 and 2, respec-
tively. After discounting, the threshold figures for CLD
costs were 23387500 Rials (2818 $) for strategy 1 and
22797054 Rials (2747 $) for strategy 2. This showed that
for the cost of CLD higher than the thresholds above, the
Table 1: Input values for the probabilities in the model. Min. and Max. values were used in sensitivity analysis.
Variable Definition Baseline Min. Max. References
P1 Prevalence of HBsAg positivity in general population 0.02 0.01 0.09 2–6
P2 Prevalence of HBcAb positivity in general population 0.20 0.15 0.40 2,3
P3 Probability of becoming HBsAg + for an HBsAg + person's spouse 0.05 0.04 0.15 8–11
P4 Probability of becoming HBsAg + for an HBsAg + person's spouse after 
receiving prevention protocol §
0.005 0 0.0125 12–23
§ See text for details.
Table 2: Input values for the costs in the model.§
Variable Definition Cost Rials (US $)*
C1 Cost of HBsAg screening 30000 (3.6)
C2 Cost of HBcAb screening 30000 (3.6)
C3 Cost of HB vaccination (one dose) 40000 (4.8)
C4 Cost of HBIG injection (single dose) 120000 (14.5)
C5 Cost of Condoms (one box) 8000 (1)
C6 Cost of HBsAb screening 30000 (3.6)
§ The direct medical costs of the interventions were extracted from the resources and tariffs of Iranian Health Ministry, Iran Pasteur Institute and 
Iranian Transfusion Organization (unpublished data).
* 1US $ = 8300 Iranian RialsBMC Infectious Diseases 2004, 4:31 http://www.biomedcentral.com/1471-2334/4/31
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respective strategies used for HBV transmission preven-
tion would be cost saving.
Sensitivity analysis
Sensitivity analysis showed that when the prevalence of
HBsAg positivity in general population (P1) varied from
the minimum to maximum, the cost per chronic HBV
infection averted varied from 1,503,440 Rials (183 $) to
2,740,560 Rials (330 $) in strategy 1 and from 1,482,620
Rials (179 $) to 2,568,310 Rials (309 $) in strategy 2 (Fig.
2).
When the prevalence of HBcAb positivity in general pop-
ulation (P2) increased from the lowest to highest, the cost
per chronic HBV infection prevented did not vary in strat-
egy 1; but in strategy 2, it decreased from 1,645,720 Rials
(198 $) to 1,561,530 Rials (188 $). Therefore, the higher
rates of HBcAb positivity made the cost of strategy 2
become remarkably lower than that of strategy 1 (Fig. 3).
Changing the probability of becoming HBsAg positive for
an HBsAg positive person's spouse after marriage (P3)
from minimum to maximum varied the cost-effectiveness
ratio from 2094370 Rials (252 $) to 558,500 Rials (67 $)
in strategy 1 and from 2,041,500 Rials (246 $) to 544,400
Rials (66 $) in strategy 2. It shows that higher spouse-to-
spouse transmission rates significantly increase the cost of
both strategies (Fig 4).
When the probability of becoming HBsAg positive for an
HBsAg positive person's spouse after receiving prevention
protocol (P4) changed from the highest to lowest, the cost-
effectiveness ratio decreased from 2,010,600 Rials (242 $)
to 1,507,950 Rials (182 $) in strategy 1 and from
1,959,840 Rials (236 $) to 1,469,880 Rials (177 $) in
strategy 2. It shows that higher efficacy of the preventive
protocol results in lower costs-effectiveness ratios (Fig. 5).
Strategy 2 was always cheaper than strategy 1 for all values
of P1, P2, P3 and P4 in the univariate sensitivity analyses
(explained above).
The results of multivariate sensitivity analysis of the two
variables P1(the prevalence of HBsAg positivity in popula-
tion) and P2 (the prevalence of HBcAb positivity in popu-
lation) revealed that the strategy 2 was always cheaper
than strategy 1 while the two probabilities varied.
Discussion
Preventing sexual transmission of HBV is not a new issue;
however, the authors did not encounter any studies
directly addressing the economic aspects of premarriage
prevention of hepatitis B in their literature review. The rea-
son can be the particular cultural backgrounds of Iranian
community in which extramarital sexual relationships
with the would-be spouse is expected to be rare due to
strong traditional and religious bans against it. Conse-
quently, the model used in this study may not be an
appropriate one for countries with remarkable cultural
difference in terms of extramarital sexual relationship
such as Western countries. On the other hand, the cultural
similarities between Iran and some other Eastern
countries can increase the external validity of our model
for policy makers in such countries.
While the prevalence of HBsAg positivity in general popula- tion (P1) varied from the minimum to maximum in sensitivity  analysis, the cost per HBV chronic infection averted varied  from 1,503,440 Rials (183 $) to 2,740,560 Rials (330 $) in  strategy 1 and from 1,482,620 Rials (179 $) to 2,568,310  Rials (309 $) in strategy 2; strategy 2 remained slightly  cheaper throughout the range Figure 2
While the prevalence of HBsAg positivity in general popula-
tion (P1) varied from the minimum to maximum in sensitivity 
analysis, the cost per HBV chronic infection averted varied 
from 1,503,440 Rials (183 $) to 2,740,560 Rials (330 $) in 
strategy 1 and from 1,482,620 Rials (179 $) to 2,568,310 
Rials (309 $) in strategy 2; strategy 2 remained slightly 
cheaper throughout the range.
When the prevalence of HBcAb positivity in general popula- tion (P2) increased from the lowest to highest limit, the cost  per chronic HBV infection prevented did not vary in strategy  1, but in strategy 2, it decreased from 1,645,720 Rials (198 $)  to 1,561,530 Rials (188 $) Figure 3
When the prevalence of HBcAb positivity in general popula-
tion (P2) increased from the lowest to highest limit, the cost 
per chronic HBV infection prevented did not vary in strategy 
1, but in strategy 2, it decreased from 1,645,720 Rials (198 $) 
to 1,561,530 Rials (188 $). Therefore, the higher rates of 
HBcAb positivity made the cost of strategy 2 become more 
remarkably lower than that of strategy 1.BMC Infectious Diseases 2004, 4:31 http://www.biomedcentral.com/1471-2334/4/31
Page 7 of 10
(page number not for citation purposes)
One of the important challenges in our study was the lack
of precise data regarding some probabilities. Most of the
studies in our literature review contained the prevalence
of HBsAg positivity (chronic HBsAg carrier state) in the
spouses of HBsAg positive people and the extent to which
it was different from the rate in general population [8-11].
Because such a rate existed in literature, we preferred to
use this prevalence rate representing the initial outcome
of sexual contact with an HBsAg positive spouse after mar-
riage. Thus, what is seen in the model (Fig. 1) as HBsAg+
final outcome does not mean getting infected with HBV;
it means getting into a chronic HBsAg carrier state. In our
model, we assumed all such cases to be chronic HBsAg
carriers that entered the chronic carrier state asymptomat-
ically or following an acute infection; 15% of such carriers
could finally develop CLD during their lifespan [1,24,25].
Therefore, it is obvious that our model have primarily
focused on more chronic outcomes of HBV infection (e.g.
we ignored the costs of acute infections). However, this
will not endanger the data robustness in our study;
instead, it will always guarantee that all of the cost-effec-
tiveness ratios calculated here are actually higher than that
would be resulted with including the costs for acute cases
which usually comprise a considerable portion of the
symptomatic cases in adults [1,24,25].
The costs of acute and chronic liver disease (CLD) due to
HBV infection in Iran were other variables for which data
was lacking. One of the important reasons we did not use
a Markov model to calculate CLD costs for Iran was the
lack of important necessary data for running a Markov
model (e.g. lack of data on age specific mortality rates,
etc.). We first calculated cost-effectiveness ratios ignoring
the costs of acute and chronic liver disease (the costs of the
morbidity averted); this surely exaggerated the calculated
cost-effectiveness ratios in the study. Thus, one should
judge them from a more optimistic point of view. In the
second step, to compensate for the lack of lifetime CLD
costs in Iranian literature, we performed a threshold anal-
ysis using the baseline values for input probabilities and
determined a threshold value for the lifetime costs of CLD
in Iran, above which the preventive interventions were
cost saving. The threshold levels for CLD lifetime costs
estimated above do not seem high costs compared with
the costs that CLD can impose on the society in terms of
direct and indirect medical costs and productivity losses
due to time spent sick or years of life lost because of pre-
mature death. The relevant medical costs or the costs asso-
ciated with the productivity losses due to CLD was not
accessible at the time of this research, so we discussed the
point through some indirect comparisons considering the
threshold we calculated for lifetime CLD costs.
Though comparing the costs of CLD in Iran with that in
the United States does not seem a standard approach, the
large differences between the threshold figure we calcu-
lated for CLD costs in Iran and the CLD costs estimations
Changing the probability of becoming HBsAg positive for an  HBsAg positive person's spouse (P3) after marriage from  minimum to maximum varied the cost per HBV chronic  infection averted from 2094370 Rials (252 $) to 558,500  Rials (67 $) in strategy 1 and from 2,041,500 Rials (246 $) to  544,400 Rials (66 $) in strategy 2 Figure 4
Changing the probability of becoming HBsAg positive for an 
HBsAg positive person's spouse (P3) after marriage from 
minimum to maximum varied the cost per HBV chronic 
infection averted from 2094370 Rials (252 $) to 558,500 
Rials (67 $) in strategy 1 and from 2,041,500 Rials (246 $) to 
544,400 Rials (66 $) in strategy 2. It shows that higher 
spouse-to-spouse transmission rates significantly increase the 
cost of both strategies.
When the probability of becoming HBsAg positive for an  HBsAg positive person's spouse after receiving prevention  methods (P4) changed from the highest to lowest, the cost  per HBV chronic infection averted decreased from 2,010,600  Rials (242 $) to 1,507,950 Rials (182 $) in strategy 1 from  1,959,840 Rials (236 $) to 1,469,880 Rials (177 $) in strategy  2 Figure 5
When the probability of becoming HBsAg positive for an 
HBsAg positive person's spouse after receiving prevention 
methods (P4) changed from the highest to lowest, the cost 
per HBV chronic infection averted decreased from 2,010,600 
Rials (242 $) to 1,507,950 Rials (182 $) in strategy 1 from 
1,959,840 Rials (236 $) to 1,469,880 Rials (177 $) in strategy 
2. It shows that higher efficacy of the preventive intervention 
results in lower costs-effectiveness ratios.BMC Infectious Diseases 2004, 4:31 http://www.biomedcentral.com/1471-2334/4/31
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(including productivity losses) mentioned in the studies
for the United States in 2001 (64,382 $) [25] may
partially reveal some facts [1,24,25]. To perform a more
realistic comparison, we used Purchasing Power Parity
(PPP) rates instead of exchange rates to convert the thresh-
old cost in Rials into PPP dollars. PPP is defined as the
numbers of units of a country's currency needed to buy in
the country the same amounts of goods and services as,
say, one US dollar would buy in the United States. The
PPP rate for Iranian Rial was extracted from the National
Health Account 2002 by Planning and Management
Organization of Iran (unpublished data) and from figures
reported by the World Bank Group. The threshold cost
using PPP rates would be equal to about 9615 to 9863
PPP $ (for 2 strategies). Therefore, even if the total CLD
costs in a country like Iran were 7-fold smaller than that
in the United States, the strategies 1 and 2 mentioned in
the model could still be cost saving.
To give a sketchy view of some of CLD costs in Iran, the
costs of a liver biopsy and those of a pharmacotherapy
regimen related to CLD was retrieved by contacting dis-
charge and accounting departments of a state-run hospital
and a major drug distributor in Tehran. The discounted
cost for an uncomplicated liver biopsy needing 1 to 2 days
of hospitalization, blood coagulation serial tests and a
special liver biopsy needle turned out to be about
2,093,778 Rials (252 $) in all state-run hospitals in Iran.
Pharmacotherapy with new antiviral and
immunomodulatory drugs is employed for treatment of
active chronic liver disease in patients with hepatitis B
[26]. The discounted cost of lamivudine, a typical exam-
ple of these drugs, can be another instance of costs CLD
imposes on many patients. A 12-month course of lamivu-
dine (Iranian brand) in Iran can cost a patient 2,521,956
Rials (304 $). If the same calculation is performed for the
foreign brand of lamivudine available in Iran (Zeffix), the
discounted cost will be 12,991,892 Rials (1565 $). In
addition, these costs may be much higher when some
more expensive drug regimens are used or more pro-
longed regimens are repeated due to chronicity or intrac-
tability of disease. The costs mentioned here can not
directly give a clue to total CLD costs and mentioning
them was to help the reader get a view of the scale of some
familiar CLD costs in Iran.
In a different approach, we converted the threshold value
into the number of productive months for a national of a
country having a GDP (Gross National Product) per cap-
ita like Iran. GDP per capita shows the amount that an
individual contributes to domestic income every year.
According to the World Bank Group, Iran had a GDP per
capita of 1641 $ in 2002, and the average annual growth
of GDP per capita in Iran for 2002 to 2006 was 4.5%.
From here, the GDP per capita in 2003 comes to be 1790
$. Assuming that the average growth of GDP per capita for
Iran will remain at 5% in the coming 25 years (the period
used for discounting the CLD threshold costs), the GDP
per capita will be 6062 $ at the end of the period. Consid-
ering such figures, the threshold calculated above would
be equal to about 6 months of productivity based on a
GDP view. The average number of Quality Adjusted Life
Years (QALY) that CLD can deduct of an Iranian's life is
not yet determined. Nevertheless, a 6-month period does
not seem a long time compared with the life years lost due
to premature mortality and the QALYs lost due to sickness
in the proportion of CLD patients with cirrhosis and
hepatocellular carcinoma only.
Finally, the fact that the strategies would be cost effective
can be further emphasized when taking into account the
costs of acute cases of HBV infection that comprise the
majority of symptomatic cases in adults and were ignored
in the model due to lack of Iranian data and for sake of
simplicity. Another similar topic that merits discussion
here is the topic of mother-to-child vertical transmission
of HBV. If a female gets into a chronic HBsAg carrier state
and remains positive for HBeAg during pregnancy, it is
very likely that her child is infected with HBV. Since a con-
siderable proportion of infected infants will get chronic
HBV carriers, this can lead to newer CLD cases further
increasing the costs of CLD. Considering this fact, the cost
of averted morbidity owing to the preventive strategies
will increase even more and the model would seem more
cost-effective.
On the other hand, the prevention protocol in our model
might seem a bit extravagantly designed when looking at
the final HBsAb test and the extradose of HB vaccine
administered when HBsAb serum levels are insufficient.
In addition, one may argue that condoms may be more
available while being nearly as protective against HBV
transmission as HBIG injection. This can be useful in
modifications poor countries can make to the model to
get similar results in lower price or with more flexible/
available choices.
The average cost-effectiveness ratios associated with the
two preventive strategies shown in the model did not dif-
fer much. The strategy 2 was always slightly cheaper than
strategy 1. When the prevalence of HBcAb positive people
in the general population (P2) rose, strategy 2 would get
remarkably cheaper.
Finally, it is noteworthy to mention the issue of compli-
ance. As explained in methods, we assumed all recipients
of the preventive interventions (strategies 1 and 2) would
be 100% compliant and there was a full coverage of such
services in the country. The reason for such assumption
was the strict regulations set by Iranian government for allBMC Infectious Diseases 2004, 4:31 http://www.biomedcentral.com/1471-2334/4/31
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premarriage individuals to undergo a battery of screening
tests in which the strategies in our model could be inte-
grated. Nevertheless, we can assume that compliance var-
iations can affect the efficacy of our prevention protocol
(e.g. with lower rates of compliance for accepting preven-
tive strategies, we will have lower efficacy of the preven-
tion protocol). As stated in results, we performed
sensitivity analysis for P4 (probability of becoming HBsAg
positive for an HBsAg positive person's spouse after
receiving the prevention protocol), which is a variable
dependent on the efficacy of the prevention protocol (see
the formula in methods). Therefore, we indirectly incor-
porated compliance into our model's sensitivity analysis.
Considering compliance issue, we may prefer strategy 1
because it includes fewer steps (e.g. it does not include
screening for HBcAb) and may be easier to administer in
a low compliance population especially that it is negligi-
bly more expensive than strategy 2.
Conclusions
Finally, we conclude that applying the preventive strate-
gies in our model for HBVsexual transmission prevention
before marriage in the countries with cultural back-
grounds similar to Iran seems cost saving. Further
investigations in the country for precise calculation of
costs of HBV infection especially the costs associated with
CLD is necessary for more accurate economic evaluations.
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